Key result
Favipiravir and Baloxavir inhibit influenza virus polymerase through different mechanisms and are promising candidate drugs for influenza infection, especially for resistant strains.
Favipiravir and Baloxavir are promising influenza virus polymerase inhibitors for the treatment of influenza, including resistant strains.
Should not yet change practice; leaves open clinical validation of polymerase inhibitors for resistant influenza.
Anti-influenza drugs are one of the most critical pathways for control of influenza virus infection. Drugs that have been developed or are developing may function via different mechanisms, and so far, inhibitors of influenza virus polymerase are among the most promising types of drugs. Favipiravir and Baloxavir, also named T-705 and Xofluza respectively, have been approved for influenza treatment in Japan and the United States. Favipiravir effectively and selectively inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses while Baloxavir specifically targets the cap-dependent endonuclease PA of influenza viruses. These two drugs have been suggested as the first candidate drugs for influenza infection treatment, especially for strains resistant to other anti-influenza drugs. This review will focus on the pharmaceutical mechanisms and anti-influenza activity of these two drugs.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2020) conducted a review in Influenza virus infection. Favipiravir and Baloxavir was evaluated. Favipiravir and Baloxavir inhibit influenza virus polymerase through different mechanisms and are promising candidate drugs for influenza infection, especially for resistant strains.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: